Poor
Mostly Inaccurate
Patient Risk:
Low
Summary
Several factual statements about manufacturing/marketing are not supported by the provided prescribing-information excerpts. Indication-related claims are partially aligned but omit key label qualifiers (adult population; adjuvant vs metastatic; testing context). No dosing, contraindications, boxed warnings, drug interactions, adverse-reaction safety, or monitoring claims were evaluated beyond general safety-warning omission.
Category Scores
Accurate Statements
Alecensa is the brand name of alectinib.
Label provided identifies the drug as ALECENSA (alectinib) (Drug/label context in excerpts).
Alecensa (alectinib) is a prescription cancer medicine.
Label context for ALECENSA as an NSCLC treatment (Indications and Usage excerpts).
Alecensa is used to treat certain patients with ALK-positive metastatic non-small cell lung cancer (NSCLC).
Indications and Usage (1.2): indicated for treatment of adult patients with ALK-positive metastatic NSCLC.
Alecensa is used when the tumor has an ALK gene rearrangement.
Indications and Usage (1.2) requires ALK positivity as detected by an FDA-approved test; ALK rearrangement is encompassed by the label’s ALK-positive testing requirement.
Unsupported Statements
Alecensa is made by Astellas Pharma.
No manufacturing/producer company information is included in the provided label excerpts.
Alecensa is made in collaboration with partner supply/manufacturing networks.
No information about partner manufacturing/supply networks is included in the provided label excerpts.
In the US, Alecensa is marketed under the Astellas Pharma brand.
No marketing/branding ownership statements are included in the provided label excerpts.
Astellas Pharma is the company listed with the product in the US.
No company listing details are included in the provided label excerpts.
Alecensa is produced through a global manufacturing supply chain.
No manufacturing supply-chain/geographic statements are included in the provided label excerpts.
Alecensa may be manufactured at facilities operated by different contract manufacturers.
No contract manufacturing/facility information is included in the provided label excerpts.
The marketing/holder of the branded product is associated with Astellas Pharma.
No marketing authorization/holder information is included in the provided label excerpts.
Contradictions
Important Omissions
The metastatic indication in the label is explicitly for adult patients and requires ALK-positive status as detected by an FDA-approved test; the AI response does not include the 'adult' qualifier or the 'FDA-approved test' selection language.
Importance:
Moderate
No mention of adjuvant indication (post-resection ALK-positive NSCLC) present in the provided label excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated statements do not include dosing/safety-critical instructions. However, multiple label-unsupported manufacturing/marketing claims could mislead on product provenance, and indication statements omit key label qualifiers (adult population and FDA-approved test selection).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Inaccurate
Primary Issue
Several non-clinical manufacturing/marketing statements are not supported by the provided FDA label excerpts, and indication statements omit key label qualifiers (adult population and FDA-approved test selection).
Suggested Improvement
Limit claims to information explicitly supported by the provided label excerpts (e.g., indications, patient selection language, dosing/administration if provided). Add the adult/prespecified test-selection qualifiers for the metastatic indication and avoid unverifiable manufacturing/marketing statements not present in the excerpts.